For a world first, the enthusiastic British authorities hope that the vaccination campaign which has started heralds the “beginning of the end”. The day is even described by some officials as “V-Day” alluding to the end of World War II. This December 8 at Coventry University Hospital, Margaret Keenan, soon to be 91, is the first patient in the United Kingdom to benefit from the promising vaccine developed by the American firm Pfizer and the German start-up BioNTech.
The British authorities after approving the recommendations of the independent regulatory agency for medicines and health products (MHRA) which ensures that the Pfizer-BioNTech vaccine meets the criteria for safety and efficacy to begin this morning the administration vaccine. For this first phase of vaccination, people over 80, medical staff and people working in retirement homes are privileged. More than 4 million people will need to receive the vaccine by the end of the month.
It should also be noted that while the efficacy of the vaccine is 95% as announced by Pfizer at the end of clinical trials, the duration of the vaccine’s immunity or its ability to stop the transmission of the virus is still a problem. unknown.
